Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
Dell'Agnello G, Maschietto D, Bravaccio C, Calamoneri F, Masi G, Curatolo P, Besana D, Mancini F, Rossi A, Poole L, Escobar R, Zuddas A; LYCY Study Group. Dell'Agnello G, et al. Among authors: zuddas a. Eur Neuropsychopharmacol. 2009 Nov;19(11):822-34. doi: 10.1016/j.euroneuro.2009.07.008. Epub 2009 Aug 28. Eur Neuropsychopharmacol. 2009. PMID: 19716683 Clinical Trial.
Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study.
Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, Faries DE, Zhang S, Biederman J. Michelson D, et al. Among authors: zuddas a. J Am Acad Child Adolesc Psychiatry. 2004 Jul;43(7):896-904. doi: 10.1097/01.chi.0000125089.35109.81. J Am Acad Child Adolesc Psychiatry. 2004. PMID: 15213591 Clinical Trial.
A comparison of North American versus non-North American ADHD study populations.
Buitelaar JK, Barton J, Danckaerts M, Friedrichs E, Gillberg C, Hazell PL, Hellemans H, Johnson M, Kalverdijk LJ, Masi G, Michelson D, Revol O, Sebastian JS, Zhang S, Zuddas A. Buitelaar JK, et al. Among authors: zuddas a. Eur Child Adolesc Psychiatry. 2006 Mar;15(3):177-81. doi: 10.1007/s00787-005-0523-2. Epub 2006 Jan 30. Eur Child Adolesc Psychiatry. 2006. PMID: 16447026
Comorbid oppositional defiant disorder and the risk of relapse during 9 months of atomoxetine treatment for attention-deficit/hyperactivity disorder.
Hazell P, Zhang S, Wolańczyk T, Barton J, Johnson M, Zuddas A, Danckaerts M, Ladikos A, Benn D, Yoran-Hegesh R, Zeiner P, Michelson D. Hazell P, et al. Among authors: zuddas a. Eur Child Adolesc Psychiatry. 2006 Mar;15(2):105-10. doi: 10.1007/s00787-006-0506-y. Eur Child Adolesc Psychiatry. 2006. PMID: 16523251 Clinical Trial.
European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder.
Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, Anderson C, Civil R, Higgins N, Lyne A, Squires L. Coghill D, et al. Among authors: zuddas a. Eur Neuropsychopharmacol. 2013 Oct;23(10):1208-18. doi: 10.1016/j.euroneuro.2012.11.012. Epub 2013 Jan 15. Eur Neuropsychopharmacol. 2013. PMID: 23332456 Free article. Clinical Trial.
159 results